RNAi Technology Market Size, Share & Trends Analysis Report By Product & Services (Products, Services), By Application (Drug Discovery & Development, Functional Genomics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

RNAi Technology Market Size & Trends

The global RNAi technology market size was estimated at USD 2.60 billion in 2023 and is projected to witness a CAGR of 14.6% from 2024 to 2030. This market growth can be attributed to the increasing prevalence of autoimmune diseases, rare disorders, and cancer across the globe. The rising demand for therapies targeting neurodegenerative disorders, genetic disorders, and cancer will drive market growth. Moreover, several studies focused on RNAi therapeutics as promising therapies for treating COVID-19 infections.

An exponential rise in the COVID-19 cases globally boosted the demand for RNAi technology. This is attributed to the research and development (R&D) investments, especially in RNAi therapeutics, including advancements in gene silencing techniques. This increased funding expedited R&D in therapies for COVID-19 and other infectious diseases. The urgency of pandemic highlighted the importance of effective antiviral treatments, and RNAi technology has shown promise. The heightened public awareness of gene silencing technologies due to the pandemic has enhanced recognition of potential, leading to increased market potential. The COVID-19 pandemic also emphasized the significance of personalized medicine, as patients responded differently to the virus.

Furthermore, the market is expected to exhibit lucrative growth over the forecast period, with many companies engaged in the investigation of new therapeutics. Companies are engaged in extensive R&D for the development of novel drugs to treat various diseases to maintain their market share. Major products present in different phases of discovery, development, or clinical phases of trials cover the treatment of cancer and cholesterol-associated disorders. Moreover, drug candidates intended for the treatment of genetic deformities are in the development phase, which is expected to contribute to market growth.

Moreover, technologically advanced drug delivery methods can aid in addressing the issue of degradation of nucleic acids caused by a multitude of serum nucleases upon administration of naked small interfering RNA (siRNA) in the bloodstream. These advanced methods include innovative delivery systems based on the principle of nanotechnology and liposome-based technology. Many laboratories have presented solutions to siRNA delivery utilizing novel nanotechnology-based carrier systems. Thereby, propelling the market growth of RNAi technology over the forecast period.

Market Concentration & Characteristics

The RNAi technology industry has seen significant innovation in recent years, driven by advances in molecular biology, biotechnology, and therapeutic development. RNAi has been increasingly used to develop therapies for genetic disorders by silencing specific genes associated with diseases. For instance, treatments for conditions like amyloidosis and certain types of hypercholesterolemia have shown promise. Moreover, numerous RNAi-based therapies are currently in various stages of clinical trials, targeting a wide range of diseases, including viral infections, metabolic disorders, and neurological conditions.

In this industry, partnerships and collaboration activities are moderately prevalent, reflecting a medium level of engagement within the industry. The collaboration is crucial for advancing the technology and overcoming the challenges associated with RNAi therapeutics. For instance, in December 2023, Innovent and SanegeneBio entered a strategic collaboration to develop an siRNA drug for the treatment of hypertension.

The regulatory impact on RNAi technology industry is significant. Regulatory agencies such as the FDA and European Medicines Agency are developing and refining guidelines for advanced therapeutics applications. These guidelines aim to establish a framework for the assessment of clinical trials, addressing issues such as off-target effects, unintended consequences, and long-term safety.

The RNAi technology industry has experienced moderate growth in recent years, driven by the rising demand for RNAi technology and the increasing R&D activities in the drug discovery and development process. For instance, in November 2020, Alnylam Pharmaceuticals, Inc. launched new Value-based Agreements (VBAs) to improve patient access to givosiran. This was expected to enhance the company’s business and boost its offerings in RNAi therapeutics.

The industry is experiencing a high level of regional expansion, indicating rapid growth and increasing market presence across different geographic regions. This expansion is driven by several factors, including the growing research activities in genomic researches and increasing epigenetic services worldwide. For instance, in May 2019, Olix Pharmaceuticals, Inc. expanded its ocular disease pipeline by adding OLX304A to treat retinitis pigmentosa. The company was utilizing its cp-asiRNA platform technology for product development.

Application Insights

Based on application, the market is segmented into drug discovery & development, functional genomics, and others. Drug discovery & development segment dominated the market with a share of 68.87% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. The capability of RNAi technology to accurately target and silence certain genes positions it as a crucial instrument in drug discovery and development. This accuracy enhances researchers' ability to study gene functions and their involvement in diseases, speeding up the process of identifying and validating new targets for therapy. In addition, an increase in investments and strategic collaborations among pharmaceutical firms to create RNAi-based treatments, and improvements in RNAi delivery techniques for better effectiveness, is expected to substantially fuel market growth. In November 2023, Gradalis has secured a USD 9.9 million grant to fund a pivotal Phase II trial evaluating their bi-shRNA therapy, Vigil, for patients with platinum-sensitive recurrent ovarian cancer. Thereby impelling the segment’s growth over the forecast period.

The functional genomics segment is expected to register a significant CAGR over the forecast period. This growth can be attributed to research efforts focused on interpreting the phenotypical expression associated with specific disease conditions. A considerable number of cancer gene therapies are developed using functional genomic technology as their foundation. Thus, projected to propel the segment growth over the forecast period.

Product & Service Insights

Based on product & service, the market is segmented into products (miRNA products, siRNA products & others) and services. The products segment dominated the market share in 2023. This is further segmented into miRNA, siRNA, and others. miRNA and siRNA have demonstrated considerable promise in therapeutic uses, particularly in the area of gene silencing, essential for addressing a wide range of illnesses such as cancer, viral infections, and hereditary conditions. Their capacity to target and dismantle mRNA molecules with high specificity allows for accurate molecular interventions, rendering them powerful instruments in contemporary medical practices. Moreover, the rising investment is anticipated to propel the advancements in the organization's product portfolio. For instance, in August 2023, ADARx Pharmaceuticals raised USD 200 million in Series C financing. The funds were used to advance its clinical programs, including the lead siRNA-based drugs ADX-324 and ADX-038. ADARx is developing an RNA-targeting platform featuring oligonucleotides for inhibition, degradation & editing, and innovative oligonucleotide delivery technologies. Thus, anticipated to fuel the segment’s growth over the forecast period.

The services segment is expected to register the highest CAGR of 16.0% over the forecast period. RNAi technology's difficulty and technical demands increase the demand for specialized companies with the right skills and equipment. Contract Research Organizations (CROs) and similar firms provide full RNAi services, from finding targets to running studies before and during clinical trials, which helps speed up the creation of new drugs. This is anticipated to drive the segment in the coming years.

End-use Insights

Based on end-use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and CROs & CMOs. The pharmaceutical & biotechnology companies segment dominated the market with a share of 56.54% in 2023. This is attributed to several factors, including ongoing research and development efforts, innovative therapies, and the introduction of advanced pharmaceutical products. In addition, the increasing demand for healthcare solutions, and advancements in biotechnology, likely contributed to the segment's stronghold in the market.

The CROs & CMOs segment is expected to register the highest CAGR over the forecast period. Outsourcing is becoming a strategic move for pharmaceutical and biotech firms aiming to cut expenses and boost operational effectiveness. Entrusting specialized service providers such as Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) with ancillary tasks like research and production allows these firms to concentrate on their primary strengths. This strategy enables them to tap into the advanced expertise and technology in the outsourcing sector. Thus, propelling the growth of the segment over the foreseeable future.

Regional Insights

North America accounted for the largest market share of 38.54% in 2023 for the market. This is attributed to the strong presence of research institutions and universities engaged in cutting-edge research in genomics, molecular biology, and biotechnology. The demand for RNAi therapeutics in research applications is likely driven by these institutions' exploration of technologies used in RNAi therapeutics. Moreover, government grants and funding programs provide researchers with resources to develop novel RNA technologies & therapeutics applications. These factors are anticipated to boost market growth in the region over the forecast period.

U.S. RNAi Technology Market Trends

RNAi technology market in the U.S. is expected to grow over the forecast period due to a advancements in RNA-based technologies & their applications across various industries and presence of key market players.

Europe RNAi Technology Market Trends

RNAi technology market in Europe was identified as a lucrative region in this industry. This can be attributed to the strong academic and research infrastructure, with institutions like the Center for Genomic Regulation (CRG) and the National Center for Biotechnology (CNB) actively researching RNA interference applications in healthcare. Several startups are entering the RNA space, developing & commercializing innovative solutions.

The UK RNAi technology market held a significant share in 2023. This is attributed to the increasing prevalence of genetic disorders & diseases, the need for more efficient and effective treatments, and the growing interest in gene-editing technologies among researchers & scientists.

The RNAi technology market in France is expected to grow remarkably over the forecast period. The geriatric population is increasing in France, leading to a rise in neurodegenerative diseases, such as Alzheimer’s & Parkinson’s.

The Germany RNAi technology market is anticipated to grow significantly over the forecast period. Germany’s strong R&D landscape in these areas is expected to improve the adoption of innovative therapies. Germany is one of the global leaders in scientific research, with renowned institutions & multiple biotechnology companies actively developing RNA-based research tools and novel therapeutics.

Asia Pacific RNAi Technology Market Trends

The RNAi technology market in Asia Pacific held highest CAGR of 16.75% over the forecast peiord. This upsurge is attributed to the high birth rate, high prevalence of genetic disorders because of various factors, such as consanguineous marriages and founder mutations. RNA oligonucleotides and RNAi techniques are used in gene therapy applications.

The China RNAi technology market is expected to grow over the forecast period. The increasing prevalence of genetic diseases and the rising need for personalized medicine are some of the major factors fueling the demand for RNA-based therapies.

The RNAi technology market in Japan is witnessing rapid growth due to the growing adoption of precision medicine and personalized healthcare in Japan is boosting the demand for RNAi applications. In addition, Japan is a major player in scientific research, particularly in biotechnology & biopharmaceuticals.

MEA RNAi Technology Market Trends

The RNAi technology market in MEAis expected to grow exponentially over the forecast period. Cancer is a major public health concern in MEA. High mortality associated with the unavailability of resources, such as diagnostics, underdeveloped healthcare infrastructure, and lack of affordable treatment options make MEA a preferred region for investments by large manufacturers. However, a limited number of institutes having advanced research facilities is hampering market growth in the region.

The Saudi Arabia RNAi technology market is expected to grow over the forecast period. This is attributed to the growing investment in biotechnology and life sciences initiatives, including R&D. In addition, extensive research studies involving sequencing can help expand the usage rate of advanced sequencing techniques in the country.

The RNAi technology market in UAE is anticipated to grow over the forecast period. In November 2023, the Hevolution Foundation collaborated with Buck Institute for Research on Aging in Saudi Arabia with an investment of USD 21 million to support novel scientific initiatives and accelerate therapeutic inventions specifically targeting aging and age-related chronic diseases such as Parkinson's, Alzheimer's, cancer, atherosclerosis (strokes and heart attacks), and diabetes type 2.

Key RNAi Technology Company Insights

Major players operating in the market are adopting product approval to increase the reach of their products in the industry and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Recent Development

• In May 2024, Codexis, Inc. has announced the successful synthesis of an oligonucleotide through an enzymatic route, intended to bolster RNA-based therapeutics manufacturing. The achievement is being showcased in a Spotlight Presentation at the TIDES USA annual meeting in Boston, MA. This milestone serves as compelling evidence to the industry of the availability of alternative manufacturing methods amid the growing demand for RNAi therapeutics.

• In April 2024, Alnylam Pharmaceuticals announced positive results from the KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension treatment. The study assessed a single subcutaneous dose of zilebesiran alongside standard antihypertensive medications. Results, presented at the 2024 ACC Annual Scientific Session, reinforce its potential with biannual dosing.

• In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche to develop and market zilebesiran, an investigational RNAi therapeutic to treat hypertension.

• In July 2023, Ionis Pharmaceuticals, Inc. expanded its agreement with AstraZeneca to collaborate on developing and marketing eplontersen in the U.S. As part of the agreement, AstraZeneca was granted exclusive rights to market eplontersen in countries outside the U.S., except certain Latin American countries.

RNAi Technology Market Report Scope

Global RNAi Technology Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global RNAi technology market based on product & service, application, end-use, and region.

• Product & Service Outlook (Revenue, USD Million, 2018 - 2030­)

  • Products

    • miRNA

    • siRNA

    • Others

  • Service

• Application Outlook (Revenue, USD Million, 2018 - 2030­)

  • Drug Discovery & Development

    • Neurology

    • Oncology

    • Infectious Diseases

    • Metabolic Diseases

    • Others

  • Functional Genomics

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030­)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • CROs & CMOs

• Regional Outlook (Revenue, USD Million, 2018 - 2030­)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait